Back to Search Start Over

Treatment of Thyroid Eye Disease-Associated Ophthalmopathy and Myopathy With Intraorbital Injection of 5-Fluorouracil and Triamcinolone Acetonide.

Authors :
Kupcha AC
Law JJ
Mawn LA
Source :
Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2024 Jan-Feb 01; Vol. 40 (1), pp. 104-108. Date of Electronic Publication: 2024 Jan 18.
Publication Year :
2024

Abstract

Purpose: The authors report a technique of local application of anti-metabolite and corticosteroid mixture in the orbit for treatment of thyroid orbitopathy with moderate-severe inflammation and muscle involvement.<br />Methods: Patients of one orbital surgeon seen between March 2019 and May 2020 with active thyroid eye disease and restrictive strabismus were considered for local treatment of the myopathic component of the disease. A mixture of 1 ml 5-FU 50 mg/ml, 0.25 ml triamcinolone 40 mg/ml, and 1 ml lidocaine 2% is injected through the skin using a 25-gauge, 1.5-inch needle into the orbit adjacent to the affected extraocular muscle. Six patients were treated in the outpatient setting and 3 patients have been treated with this intervention intraoperatively at the time of orbital decompression. One was treated with the mixture reconstituted with hyaluronic acid (Healon GV) to address postoperative medial rectus fibrosis to the medial wall, this mixture was applied topically in the operative field and not injected.<br />Results: All patients had subjective improvement in the eye movement limitation and 2 patients had a change in motility on exam that was temporally correlated to injections. One patient did not disclose high-dose aspirin intake before injection and experienced a retrobulbar hemorrhage immediately following injection which was successfully treated. No complications were noted as a result of the medication itself.<br />Discussion: The combination of 5-fluorouracil and triamcinolone acetonide for orbital treatment may be a useful adjunct in treating patients with ongoing inflammatory activity, both in the office and in the operating room. The novel combination may optimize ophthalmic outcomes, modifying disease course in some patients.<br />Competing Interests: The authors have no financial or conflicts of interest to disclose.<br /> (Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.)

Details

Language :
English
ISSN :
1537-2677
Volume :
40
Issue :
1
Database :
MEDLINE
Journal :
Ophthalmic plastic and reconstructive surgery
Publication Type :
Academic Journal
Accession number :
38241622
Full Text :
https://doi.org/10.1097/IOP.0000000000002541